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 Glaucoma is an anterior optic neuropathy with charac-
teristic changes of the optic disc due to loss of retinal gan-
glion cells. The major risk factor for the disease is elevated
intraocular pressure (IOP). Glaucoma is the second leading
cause of blindness worldwide, projected to affect more than
60 million people by 2010 [1], and with the increasing aver-
age human life expectancy, the prevalence is rising. Primary
open angle glaucoma (POAG, OMIM 137760) is the major
subtype, and to date three genes, namely, Myocilin (MYOC),
Optineurin (OPTN), and WD repeat-containing protein 36
(WDR36), have been reported to be primarily responsible for
POAG [2-4]. POAG shows autosomal dominant inheritance
with variable penetrance. The presence of many sporadic pa-
tients points to a complex genetic etiology. Myocilin (MYOC,
OMIM 601652) is the most frequently mutated gene in POAG,
accounting for 3%-4% of all the cases. To date, more than 70
missense variants in MYOC have been reported to be causal
for POAG.
To investigate the role of MYOC in POAG patients from
The Netherlands, we analyzed 30 families and described a
novel mutation in exon 3 of MYOC that segregated with the
disease in two different families from The Netherlands and
was found to have the same disease-associated haplotype.
Functional characterization strongly suggested it to be a patho-
logic variant.
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Purpose: Glaucoma is the second most prevalent cause of blindness worldwide, projected to affect more than 60 million
people by 2010, 75% of which represents primary open angle glaucoma (POAG). Of the three genes, namely, Myocilin
(MYOC), Optineurin (OPTN), and WD repeat-containing protein 36 (WDR36), which have been shown to cause POAG
when defective, MYOC is the most frequently mutated gene, accounting for 3%-4% of all POAG cases. The purpose of
this study was identification and functional characterization of MYOC mutations in adult-onset, high-pressure POAG
patients from The Netherlands.
Methods: The following criteria were required for study participants to be included: have at least two affected family
members, an age of diagnosis of more than 35 years, intraocular pressure (IOP) of more than 22 mmHg, glaucomatous
optic neuropathy in both eyes, visual field loss consistent with assessed optic neuropathy in at least one eye, and an open
anterior chamber angle without morphological abnormalities by gonioscopy. Sequence analysis was performed in ge-
nomic DNA of 30 probands for the protein coding region of the MYOC gene. A Chinese hamster ovarian cell line (CHO-
K1) was used to express wild type and mutant MYOC protein. Detergent solubility of MYOC was assayed and its secre-
tory property was analyzed by immunoprecipitation.
Results: We recruited 250 individuals from 30 families (120 affected and 130 unaffected family members) with a positive
history of POAG. We identified a novel mutation c.1288T>C (p.Phe430Leu) in exon 3 of MYOC in two unrelated families
showing the same haplotype around the mutant allele. The novel mutation segregated completely with the disease in these
families and was absent in 250 ethnically matched controls. All patients harboring this mutation showed severe glaucoma-
tous damage, pointing to the deleterious effect of this mutation. Compared to the wild type, the mutant protein was less
soluble when extracted with Triton X-100 and was secretion-defective.
Conclusions: The novel MYOC mutation, p.Phe430Leu, has the same origin in both POAG families from The Nether-
lands. The pathogenic nature of this mutation is suggested by the severe phenotype of mutant patients and mistrafficking
of mutant protein as observed for other severe disease-causing mutations of MYOC.
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METHODS
Selection of subjects:  We conducted a cross-sectional study
on native Dutch patients with inherited POAG. The study was
done in accordance with the principles of the Declaration of
Helsinki and with the approval of the Ethics Committee. The
broad purpose of the entire program is to identify novel genes
causing a familial form of high-tension POAG. In the first
phase of the program, we analyzed the occurrence of MYOC
mutations. We included subjects with an age of diagnosis of
more than 35 years, IOP of more than 22 mmHg measured by
applanation tonometry in both eyes on two glaucoma medica-
tions, glaucomatous optic neuropathy in both eyes at fundus-
copy, visual field loss consistent with assessed optic neuropa-
thy in at least one eye, an open anterior chamber angle with-
out morphological abnormalities by gonioscopy, and at least
two other affected first-degree family members.
Clinical examination:  We recorded the ophthalmic and
general medical history, and evaluated the best-corrected vi-
sual acuity (BCVA) with use of Snellen charts. The clinical
examination included slit-lamp inspection of the anterior eye,
IOP measurement by Goldmann applanation tonometry, ante-
rior chamber angle evaluation by gonioscopy, corneal thick-
ness calculation by ultrasound pachymetry, and fundus ex-
amination including optic disc assessment.
All study participants underwent static automated white-
on-white Swedish Interactive Thresholding Algorithm (SITA)
perimetry (SITA fast strategy, program 30-2, Humphrey pe-
rimeter; Carl Zeiss Meditec, Dublin, CA). In addition, a mor-
phometric analysis of the optic disc was performed by the
Heidelberg Retina Tomograph II (HRT II; Heidelberg Engi-
neering, Heidelberg, Germany) as described elsewhere [5].
An ophthalmic photographer masked to the results of the pre-
vious tests conducted the examination. A mean topography of
three images was generated in a 15°x15° frame, and the con-
tour line was drawn on the mean image. Disc and cup areas
were analyzed directly by custom software (version 2.01b,
Heidelberg Engineering, Heidelberg, Germany) using the stan-
dard reference plane. The HRT Moorfields regression analy-
sis was used for classification of the optic disc [6].
We have included subjects who were at least 35 years old
when POAG was diagnosed. Diagnosis of POAG was given
when IOP was more than 22 mmHg, which was measured by
applanation tonometry in both eyes on two glaucoma medica-
tions, and glaucomatous optic neuropathy was present in both
eyes at funduscopy as well as when visual field loss was con-
sistent with assessed optic neuropathy in at least one eye.
Genomic DNA isolation, polymerase chain reaction, and
sequencing analysis:  EDTA-anticoagulated venous blood was
collected after obtaining the informed consent from the par-
ticipating individuals. Genomic DNA was isolated from EDTA
blood using standard procedures [7]. A panel of 250 anony-
mous healthy Dutch control subjects was tested for the pres-
ence of the novel variant identified in this study. In the initial
phase of the program, we routinely screened the open reading
frame of MYOC to exclude the families with any mutation in
this gene. For the results reported in this study, 30 probands
(one patient per family) were screened for mutation in MYOC.
The primers for amplification and sequencing of the open read-
ing frame and splice junctions of MYOC are given in Table 1.
The chromatograms were analyzed for the presence of variant
alleles with the help of Vector NTI software (Invitrogen, Breda,
The Netherlands).
Microsatellite marker analysis:  A panel of five
microsatellite markers were selected around MYOC spanning
about 2.7 Mb of genomic DNA. The genomic location and the
primer sequences are given in Table 2. After amplifying each
locus with fluorescent-labeled primers, the products were run
in an ABI 3700 sequencing machine and the genotypes were
scored with Genemapper (Applied Biosystems, Ijssel, The
Netherlands). Haplotypes were constructed manually.
Site-directed mutagenesis on MYOC cDNA and cell cul-
ture: Human full-length MYOC cDNA was cloned into
pcDNA3.1 vector (Invitrogen). Mutations in MYOC cDNA
were introduced by a polymerase chain reaction (PCR)-based
method using a QuickChange II Site-Directed Mutagenesis
kit (Stratagene, La Jolla, CA) and specific primers. The sense
primer sequence with the altered base in red for p.Phe430Leu
MYOC is 5'-GCA GTC AGT CGC CAA TGC CCT CAT CAT
CTG TGG CAC CTT G-3'. Primers for p.Cys245Tyr and
p.Tyr437His are the same as reported elsewhere [8]. All con-
structs were verified by direct sequencing.
The same number of CHO-K1 cells (American Tissue Cul-
ture Collection, Manassas, VA) were transfected with plas-
mids containing wild type or different mutant MYOC cDNAs
by FUGENE 6 according to manufacturer’s protocol (Roche
Diagnostics, Rotkreuz, Switzerland) with a ratio of 3 µl trans-
fection reagent per µg DNA. Cells were used within three days
after transfection.
Monitoring Myocilin secretion:  Cells were incubated with
media containing 20 µCi/ml (35S) cysteine and (35S) methion-
ine (Anawa, Wangen, Switzerland) for 24 h. Culture media
were collected and centrifuged to remove cell debris. The su-
pernatant was immunoprecipitated (IP) with rabbit polyclonal
anti-human MYOC peptide (amino acids 188-204) antibody
[9] bound to protein A Dynabeads® (Invitrogen). IP proteins
were denatured in SDS sample buffer containing 20% β-
mercaptoethanol and resolved by 10% SDS-PAGE. The gel
was treated with EN3hance (Perkin Elmer, Walthum, MA) and
radioactivity was detected by Bio-imaging Analyzer (BAS-
1800II, Fujifilm, Dielsdorf, Switzerland).
Monitoring Triton X-100 solubility of intracellular
Myocilin:  Cells were washed twice with ice-cold PBS and
lysed in buffer containing 100 mM Tris-HCl (pH 7.4), 3 mM
EGTA, 5 mM MgCl2, 0.5% Triton X-100 (Tx, Sigma, Basel,
Switzerland), protease inhibitor cocktail (Roche, Rotkreuz,
Switzerland), and 1 mM Phenylmethyl sulfonylfluoride
(PMSF, Sigma) for two min on ice. The concentration was
5x106 cells per ml lysis buffer. After centrifugation, the super-
natant containing Tx-soluble proteins was immunoprecipitated
for MYOC or GAPDH (Ambion, Rotkreuz, Switzerland). The
cell remnants were washed twice with ice-cold PBS, scrapped
in 300 µl PBS containing protease-inhibitor cocktail and 1
mM PMSF, and centrifuged. The pellet was sonicated and de-
natured in 50 µl SDS sample buffer containing 9 M urea. Tx-
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insoluble proteins from samples equivalent to 2x105 cells were
analyzed by 10% SDS-PAGE and western blot, using anti-
bodies against MYOC (1:800 dilution) or β-actin (Sigma,
1:3000 dilution) and appropriate horseradish peroxidase-con-
jugated secondary antibodies (Amersham Bioscience,
Piscataway, NJ). The signals were detected by enhanced chemi-
luminescence (Amersham Bioscience).
RESULTS
 Two hundred and fifty individuals, representing 30 unrelated
families with a positive history of POAG (120 affected and
130 unaffected family members), were enrolled in our present
study. All affected study participants had an IOP of more than
22 mmHg and an age of diagnosis of more than 35 years. The
mean age of diagnosis was 52.7±14.8 years. Ophthalmic and
medical history did not reveal any other ocular or systemic
disorder. For sequencing the open reading frame of MYOC,
the proband from each family was used.
Identification of a novel variant in MYOC: A novel vari-
ant (c.1288T>C) that would result in a nonconservative amino
acid change (p.Phe430Leu) was discovered in exon 3 of MYOC
in two “unrelated” families from The Netherlands (Figure 1A).
All the affected members were heterozygous for the change.
The variant segregated completely with the disease in both
families (Figure 1B,C) and was absent in 250 ethnically
matched controls selected from the general population with-
out any history of glaucoma. The phenylalanine at this posi-
tion was conserved in mammals. As reported by almost every
study on MYOC, the two polymorphisms (-83G>A and
c.227G>A) in the promoter and exon 1 of MYOC, respectively,
were found in complete linkage disequilibrium in the patients
(data not shown).
c.1288T>C is part of the same haplotype in two primary
open angle glaucoma families:  Five microsatellite markers
near MYOC were selected from 1q24 to perform the haplo-
type analysis in the two affected families (Figure 1B,C and
Table 2). The marker panel covered 2.7 Mbp of genomic DNA.
Four individuals from family W05-125 and three from family
W05-295 were haplotyped for these markers. All the mem-
bers carrying the mutant allele showed the same haplotype,
suggesting that the two families are ancestrally related.
p.Phe430Leu Myocilin mutant individuals show severe
glaucoma phenotype:  The detailed phenotypic characteriza-
tion of the probands with the novel MYOC variant is described
in this section.
In Family W05-125, a 76-year-old female Caucasian pa-
tient (individual II-4 in Figure 1B), was diagnosed to have
POAG at the age of 49 years. Despite laser trabeculoplasty of
both eyes and treatment with bimatoprost and dorzolamide/
timolol eyedrops in both eyes, she had an IOP of 23 mmHg
and 30 mmHg in the right and left eye, respectively, and wors-
ening visual fields. When she was included in the study, she
had glaucomatous-affected visual fields and optic discs where
both eyes showed a superior peripheral nasal step in the vi-
sual fields (caused by loss of corresponding bundles of pe-
ripheral arcuate nerve fibers) and the optic discs of the right
and left eye are “outside normal limits” and “borderline”, re-
spectively, as scored by the HRT Moorfields regression analy-
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TABLE 1. PRIMER SEQUENCES AND POLYMERASE CHAIN REACTION CONDITIONS FOR AMPLIFYING THREE EXONS OF MYOC
                                                               Annealing           Amplicon
                                                              temperature   Mg2+     size
Exon    Forward primer (5'-3')      Reverse primer (5'-3')       (°C)       (mM)     (bp)
----   -------------------------   ------------------------   -----------   ----   --------
1      1F-GGCTGGCTCCCCAGTATATA     6R-CTGCTGAACTCAGAGTCCCC        58        2.0      782
2      7F-AACATAGTCAATCCTTGGGCC    7R-GAATAAAGACCACGTGGGCAC       52        2.0      237
3      8F-TTATGGATTAAGTGGTGCTTCG   13R-AGCATCTCCTTCTGCCATTG       58        2.5      872
For sequencing of exon 1, two nested primers were used: 3F (5'-AGT GGC CGA TGC CAG TAT AC-3') and 3R (5'-CTG GTC CAA GGT
CAA TTG GT-3'). A similar method was used to sequence exon 3, the two nester primers were: 10F (5'- ATA CTG CCT AGG CCA CTG GA-
3') and 10R (5'- CAA TGT CCG TGT AGC CAC C-3'). Exon 2 was sequenced with the same primers used for PCR. All the primers were
obtained from the literature [37].
TABLE 2. MICROSATELLITE MARKERS USED FOR HAPLOTYPING THE MYOC VARIANT P.PHE430LEU
                                                                     Genomic      Amplicon
                                                                     location    size range
Marker name   Forward primer (5'-3')     Reverse primer (5'-3')       (1q24)        (bp)
-----------   -----------------------   -------------------------   ----------   ----------
D1S2851       TCTTCCCACCACTGCC          TTTATATTTGTATTCCTACTGCCCA   168.6 Mbp     169-199
D1S452        TAATGGGTTCAGTGGACCTT      TGCAGTTCCATATTCCAGGT        168.8 Mbp     218-230
MY-3          GTTGGGAGATGTGATTGCAG      AGATGGAGGTGGGAAAGTGT        169.87 Mbp    150-160
MYOC          Not applicable            Not applicable              169.87 Mbp       NA
MY-5          TCTCTGTCCCTGCTACGTCTT     GCACCCATACCCCAATAATAG       169.88 Mbp    244-254
D1S2790       AAAATGCTCATTAGTCCAGAAAG   TGGCTATGTTTTACTAGCTCAAG     171.3 Mbp     240-260
The genomic locations are obtained from the UCSC genome browser. The location of MYOC is shown in the table. Mbp, Mega base pairs. The
genomic location is approximate and measured from the telomere of 1p. In the “Amplicon size range” column, NA indicates not applicable.
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sis 4 (Figure 2A). Gonioscopy revealed an open angle (grade
III) in both eyes. Trabeculectomy was done in both eyes and
IOP was reduced to less than 15 mmHg.
The other affected siblings (Figure 1B) were treated in
different clinics and were reported to have comparable sever-
ity of the disease. Individual II-2 also underwent a
trabeculectomy in both eyes.
In Family W05-295, a 40-year-old male Caucasian pa-
tient (individual II-1 in Figure 1C) showed glaucomatous af-
fected visual fields and optic discs in both eyes (Figure 2B).
His initial IOP was 36 mmHg in both eyes. Gonioscopy re-
vealed an open anterior chamber angle (Shaffer’s grade III) in
both eyes. Treatment with latanoprost/timolol and
brinzolamide eye drops only reduced IOP to 26 mmHg and 24
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Figure 1. The p.Phe430Leu mutation in the
Myocilin gene and a common disease hap-
lotype.  A: The chromatogram shows the
heterozygous mutation (c.1288T>C;
p.Phe430Leu; arrow) in exon 3 of MYOC.
B: Individual II-4 (arrow) in family W05-
125 is the proband. The haplotypes for
microsatellite markers are shown. The dif-
ferent alleles are given by the amplicon
lengths. The “red haplotype” contains the
mutant allele; C: Similar representation as
B of the mutant (red) haplotype is shown
but for family W05-295. Individual II-1
(arrow) is the proband. The dotted line
around the alleles at D1S2851 (B,C) de-
notes the difference in allele sharing. Note
that the mutant (red) haplotype is the same
between the two families with the same
mutation (except at D1S2851).
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Figure 2. Phenotypic characterization
of the probands with p.Phe430Leu
mutation in the MYOC gene.  Each
panel has two parts; the upper part
depicts the visual field printouts of
the Humphrey Field Analyzer (HFA)
and the lower part shows screenshots
from Heidelberg Retina Tomograph
II (HRT) analysis to detect loss of the
papillary neuro-retinal rim. The right
and left columns correspond to the
right and left eyes of the probands,
respectively. A: HFA and HRT results
for proband of W05-125 (II-4 in Fig-
ure 1B) is shown. The large dark ar-
eas in the HFA results correspond to
glaucomatous scotomas due to nerve
fiber layer defects. HRT scans dem-
onstrate glaucomatous increased op-
tic disc cupping (red areas) and sus-
pect (yellow exclamation marks) or
manifest pathological (red crosses)
neuro-retinal rim measures (accord-
ing to the Moorfield’s regression
analysis) within the different quad-
rants of the optic disc. B: A similar
representation as A is shown but for
proband of W05-295 (II-1 in Figure
1C). The results are less severe than
in proband W05-125, however, a na-
sal step characteristic for glaucoma
can be observed in HFA, and a
thinned neuro-retinal rim (blue-green
area) can be seen by HRT. C: HFA
and HRT results for a 55-year-old,
unaffected individual from W05-125
are shown for comparison. HFA re-
sults indicate that there is no darken-
ing due to glaucomatous defects on
HFA. The small temporal black area
corresponds to the physiological
blind spot. HRT results show no thin-
ning of the neuro-retinal rim is vis-
ible.
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mmHg in the patient’s right and left eye, respectively. For better
IOP management, trabeculectomy was done in both eyes,
which resulted in IOP being less than 15 mmHg in both eyes.
The patient’s father (individual I-1 in Figure 1C) and paternal
grandmother also had POAG.
For comparison, results of the visual field and HRT analy-
sis of a 55-year-old, unaffected female from W05-125 is given
in Figure 2C. The person is not depicted in the pedigree. She
tested negative for the p.Phe430Leu mutation. She does not
show any (glaucomatous) visual field loss (Figure 2C, upper
part) as present in the two probands described above.
p.Phe430Leu mutant Myocilin protein is secretion-defec-
tive and becomes detergent insoluble:  Myocilin is a secreted
protein. Reduced secretion of mutant MYOC is reported to be
a major determinant for pathologic variants in MYOC [8].
When expressed in CHO-K1 cells in contrast to wild type
MYOC (Figure 3A, lane 2), the mutant (p.Phe430Leu) pro-
tein showed much less secretion (Figure 3A, lane 4). Only a
minor band at about the 55 kDa position was observed. For
comparison, two reported mutations in MYOC, namely
p.Cys245Tyr [10] and p.Tyr437His [2], were used in the same
assay. These mutant proteins also showed reduced secretion
(Figure 3A, lanes 3 and 5). This experiment strengthened our
assumption that the missense change (p.Phe430Leu) identi-
fied in this study was pathologic.
In the intracellular fraction, the deleterious effect of
p.Phe430Leu MYOC was tested by its solubility in Triton X-
100. It was reported that as the severity of the mutation in-
creases, the Tx solubility of the mutant protein decreases [11].
When expressed in CHO-K1 cells, a major fraction of wild
type MYOC were found in Tx soluble fraction (Figure 3B,
lane 2) whereas the p.Phe430Leu mutant protein was absent
(Figure 3B, lane 4). As mentioned in the previous paragraph,
the two reported mutations also showed poor Tx solubility
comparable to p.Phe430Leu (Figure 3B, lanes 3 and 5).
Western blotting performed with the Tx insoluble frac-
tion showed that practically the entire amount of the
p.Phe430Leu mutant protein remained in this fraction, prov-
ing the reduced solubility of the mutant protein in Tx (Figure
3C, lane 4). In comparison, the two reported mutations also
showed similar effect albeit with a higher quantity (Figure
3C, lanes 3 and 5). This could be due to the variable transfec-
tion efficiencies among different mutants. Also, in the Tx in-
soluble fraction for the wild type MYOC (Figure 3C, lane 2),
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Figure 3. Functional characterization of the p.Phe430Leu mutation in Myocilin.  A: Immunoprecipitation assay is used to monitor secretory
properties of Myocilin. Lane 2 is the wild type protein and lane 4 is the mutant protein for p.Phe430Leu. Lanes 3 and 5 contain two reported
mutations (p.Cys245Tyr and p.Tyr437His, respectively) that are used for comparison. Note the lack of secretion for all three mutant proteins
compared to the wild type. B: Immunoprecipitation for the Triton X-100 soluble fraction of intracellular Myocilin is illustrated. Note the
absence of the mutant proteins in this fraction compared to the wild type. GAPDH is the housekeeping protein for loading reference. C:
Western blotting was used to detect Myocilin in the Triton X-100 insoluble fraction. Note the abundance of all three mutant proteins compared
to the wild type. β-Actin is the housekeeping protein for loading reference. CHO-K1 cells were used to express wild type and mutant MYOC
proteins. The loading order of the gel was identical in all three panels: lane 1, vector only; lane 2, wild type Myocilin protein; lane 3,
p.Cys245Tyr mutant Myocilin; lane 4, p.Phe430Leu mutant Myocilin (this study); and lane 5, p.Tyr437His mutant Myocilin. The single letter
amino-acid codes are used in the figure due to lack of space. The numbers on the left-hand side of each panel denote the molecular weight
range. This figure shows that the p.Phe430Leu mutation diminishes the secretory properties of Myocilin and makes it highly insoluble in
Triton X-100.
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a band was observed which was comparable to that of the
mutant, p.Phe430Leu. This was due to the overexpression of
wild type MYOC in the transfection where the cells could not
handle the large excess of protein properly, resulting in an
imperfectly processed insoluble fraction. To assess the effect
of the mutations on the protein, the distribution of total pro-
tein into the Tx soluble and insoluble part should be taken
into account. The results clearly showed that almost the entire
amount of the mutant protein for p.Phe430Leu remained in
the insoluble fraction whereas the wild type MYOC was dis-
tributed in approximately equimolar amounts.
DISCUSSION
 Glaucoma is a progressive optic neuropathy responsible for
12.3% of the total blind population in the world. POAG is the
most common form of glaucoma. It accounts for more than
75% of primary glaucoma except in people of eastern Asian
(Mongoloid) descent where angle closure glaucoma is more
prevalent [12]. In POAG, early identification of affected indi-
viduals can help to prevent visual damage by early treatment
of the disease [13]. Blindness due to POAG occurs in an esti-
mated 4% of cases in a white population but is more common
(8%) and occurs at an earlier age in a nonwhite population
[14]. Understanding the genetic background of POAG will
facilitate identification of high-risk individuals as well as es-
timation of the severity of the glaucoma.
In this article we report a novel missense mutation
(p.Phe430Leu) in exon 3 of MYOC. The two Dutch POAG
families described here showed segregation of the disease with
the mutation (p.Phe430Leu), which might be an indication for
the deleterious effect of the nonsynonymous substitution.
However, due to lack of family members from the younger
generation, we are unable to study the penetrance of the muta-
tion. Haplotype analyses revealed that both families inherited
the mutation through the same ancestral chromosome. A dif-
ferent allele of the first marker, D1S2851 (Figure 1B,C; alle-
les with a stippled line), suggested two possibilities: (1) a his-
torical recombination at that locus or (2) an effect of a replica-
tion slippage since the difference is only two nucleotides i.e.
one repeat unit. The average recombination frequency around
this marker is higher than that of the downstream region (1.7
cM/Mb compared to less than 1.0 cM/Mb; data from the UCSC
genome browser), which made recombination a likely event
at D1S2851.
The pathogenesis in POAG caused by MYOC defects is
yet unknown. However, approximately 97% of the mutations
are in exon 3 of the gene coding for an olfactomedin-like do-
main, which points to its crucial function. The p.Phe430Leu
mutation is also in this domain and is conserved among all
other mammalian Myocilins, which is indicative of its impor-
tance. While some MYOC mutations like p.Pro370Leu are
found in almost every population studied [15], others (for ex-
ample, p.Gln48His in India) are present only in specific popu-
lations [16,17]. Thus, the novel mutation p.Phe430Leu, re-
ported in this study, could be a prevalent mutation in the Dutch
population. We plan to screen a large cohort of POAG pa-
tients from The Netherlands to determine the prevalence of
this mutation.
A search for reported MYOC mutations in the human gene
mutation database [18] revealed 64 published missense muta-
tions. Two different blocks of 20 codons, 361-380 and 420-
440, contain 11 and 9 mutations, respectively, which account
for more than 30% of the mutations (regions A and B in Fig-
ure 4). Interestingly, codon 430 is in the middle of the second
region (codons 420-440, region B in Figure 4). Both of these
regions are in the olfactomedin domain of the protein. Although
we cannot accurately predict the exact function of these re-
gions in the olfactomedin domain, the aromatic residue Phe at
codon 430 might be crucial for the correct spatial orientation
of the cysteine residue at codon 433 involved in disulfide bonds
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Figure 4. Distribution of the missense mutations in the Myocilin gene.  The diagram illustrates MYOC and its protein. The boxes represent the
encoded regions by each exon (exon and codon numbers given below the diagram). The gray oval shows the conserved olfactomedin domain,
and the location of the two highest mutable regions are shown by black bars (marked regions, A and B). The codons 361-380 (A) contain 11
mutations and codons while 421-440 (B) contain nine mutations. Mutations reported from regions A and B together account for more than
30% of the total missense mutations in MYOC reported to date (20 out of 64). Note that the novel mutation p.Phe430Leu is located in the
middle of region B. The reported mutations are retrieved from the human gene mutation database.
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[19,20]. Fautsch et al. [19] described that the mutation at codon
433 (Cys to Arg) abolishes the secretory properties of the pro-
tein similar to what we observed in this study for p.Phe430Leu
(Figure 3).
The MYOC gene encodes a 504-aa polypeptide with a
theoretical molecular mass of 56.9 kDa. In ocular tissues, the
MYOC protein is mainly localized within the trabecular mesh-
work, the Schlemm’s canal, the sclera, the ciliary body, the
retina, and the optic nerve [21,22]. The function of the polypep-
tide is still unknown, but its colocalization with extracellular
matrix proteins such as fibronectin, laminin, or type IV col-
lagen [23,24] supports that at least part of its role is performed
in the extracellular environment. As expected, Myocilin is
observed to be secreted in the aqueous humor [25-27]. In con-
trast, the glaucoma-causing Myocilin mutations that have been
tested prevent the mutant polypeptides from being secreted
[26,28] and decrease the expressed protein’s solubility in Tri-
ton X-100 [11]. In our opinion, the defective secretion could
be due to mistrafficking caused by misfolding of the mutant
protein and possibly by the formation of insoluble aggregates.
This experiment strongly suggests that p.Phe430Leu is a patho-
logic variant.
Gobeil et al. [8] showed that wild type and mutant MYOC
proteins interact, and these heterodimeric complexes are not
secreted. This proved the hypothesis of several reports from
genetic [29-32] and biochemical [26,33-35] viewpoints that
the MYOC mutants that cause autosomal dominant POAG
probably act through a dominant negative mechanism caused
by the intracellular accumulation of mutant proteins. In our
study, the mutant MYOC protein for p.Phe430Leu was always
found in heterozygously affected individuals, and it was re-
tained inside the cell, implicating that this mutation also acts
through the same dominant negative mechanism.
Phenotypic characterization revealed severe high-pressure
glaucomatous visual field damage, and HRT analysis showed
significant thinning of the papillary neuroretinal rim, which is
in contrast to an unaffected control subject with wild type
MYOC sequence (Figure 2). Carriers of the novel mutation
had a high risk to undergo filtering glaucoma surgery. In our
present study, three out of five patients underwent
trabeculectomy, which contrasts the results of a large study in
France where only 10% of high-tension POAG patients un-
derwent trabeculectomy [36]. These clinical data support the
genetic and biochemical findings pointing to the deleterious
effect of Phe to Leu substitution at codon 430 of the Myocilin
protein.
The novel missense change (c.1288T>C; p.Phe430Leu)
in MYOC exon 3 was found to segregate with POAG in two
families from the Netherlands and was absent in 500 chromo-
somes from control individuals. The affected individuals rep-
resent severe glaucomatous damage, which had to be treated
surgically; the mutant protein was secretion-defective and not
soluble in Triton X-100. Our data strongly suggest that
p.Phe430Leu is a novel pathologic MYOC mutation causing
high-pressure POAG.
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